Xcout Intel
Phlox Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to Phlox Therapeutics among biotechnology companies — ranked by similarity to what Phlox Therapeutics actually does, not by market-cap band.
Subscribe to see Phlox Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Phlox Therapeutics
Phlox Therapeutics is a private biotechnology company pioneering RNA-based gene therapies to alleviate and cure severe genetic heart diseases and cardiomyopathies. Headquartered in Naarden, Netherlands, the company focuses on innovative cardiovascular treatments.
Phlox Therapeutics at a glance
Phlox Therapeutics is a biotechnology company headquartered in Netherlands. Its most recent funding round, Seed, closed in May 2022. Xcout tracks 5 named people at Phlox Therapeutics, including Margien Boels (Director of Operations).
Phlox Therapeutics leadership
- Margien BoelsDirector of Operations
- Eva van RooijCSO (founder)
- Yigal PintoCMO (founder)
- Rianne EllenbroekNon-executive Director
- Ross GordonObserver
Phlox Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | Undisclosed | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Phlox Therapeutics competitors
Ranked by semantic similarity — how close each company is to Phlox Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Cardior Pharmaceuticals GmbH is a clinical-stage biopharmaceutical company headquartered in Hannover, Germany. Established in 2016, the company focuses on discovering and developing RNA-based therapeutics for the prevention and treatment of heart diseases.
Biotech
Nuevocor is a biotechnology research company with its headquarters located in Singapore and additional operations in the United States and France. The company focuses on developing breakthrough gene therapies to treat untreatable cardiomyopathies.
Similar biotechnology company
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
BioTech
River BioMedics is a Dutch biotechnology company headquartered in Enschede, Netherlands, founded in 2018. The company focuses on cardiovascular drug discovery by utilizing proprietary 3D human engineered heart tissue models to address unmet medical needs.
Similar biotechnology company
NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm currently in the clinical development phase, committed to enhancing therapeutic options for individuals living with metabolic diseases. The company's primary experimental treatment, obicetrapib, is an innovative, selective agent designed to inhibit Cholesteryl Ester Transfer Protein (CETP). Clinical trials have shown this compound to be effective in both lowering "bad" low-density lipoprotein cholesterol (LDL-C) and significantly elevating "good" high-density lipoprotein cholesterol (HDL-C) simultaneously. Founded in 2019, this Dutch company maintains its headquarters in Naarden.
Similar biotechnology company
XyloCor Therapeutics is a clinical-stage biopharmaceutical company headquartered in King of Prussia, Pennsylvania, focused on developing novel gene therapies for advanced coronary artery disease. The company is dedicated to improving patient outcomes through innovative cardiovascular treatments.
Similar biotechnology company
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia dedicated to developing advanced RNA-based treatments against genetic diseases. The company maintains its headquarters in Paterna and Valencia, Spain.
Similar biotechnology company
ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company located in San Diego, California. The company is committed to developing cutting-edge RNA-targeted therapeutics to treat various genetic and severe diseases. ADARx focuses on translating scientific research into life-saving medicines through its proprietary drug discovery pipeline.
Life Sciences (Therapeutics)
DTx Pharma, Inc. is a privately held biotechnology company based in San Diego, California, that addresses the challenges associated with delivering RNA-based therapeutics.
Similar biotechnology company
Edgewise Therapeutics is a biopharmaceutical company that develops novel therapeutics for individuals facing serious cardiovascular diseases, such as hypertrophic cardiomyopathy and heart failure. The company focuses on muscle science and precision therapies to address unmet medical needs in patients and families.
Biotech
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
Similar biotechnology company
InteRNA Technologies is a venture-backed biotech and life sciences company founded in 2008 and headquartered in Utrecht, Netherlands. The company specializes in the development of microRNA (miRNA)-focused drug pipelines and therapeutics. It operates within the biopharmaceutical sector, supported by various institutional backers and investors.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Phlox Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Phlox Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →